https://pharvaris.com/
Pharvaris | Late-Stage Biopharma Company Focused on HAE
Apr 27, 2026 - Pharvaris is a late-stage biopharma company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks.
late stagefocused onpharvarisbiopharmacompany
https://www.biospace.com/press-releases/pharvaris-presents-deucrictibant-long-term-extension-data-for-both-the-prophylactic-and-on-demand-treatment-of-hae-at-the-bradykinin-symposium-2024
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand...
https://pharvaris.com/clinical-trials/
Deucrictibant Clinical Trials in HAE | Pharvaris
clinical trialshaepharvaris
https://healthheraldgrenada.com/article/872258101-pharvaris-announces-positive-topline-data-from-rapide-3-pivotal-study-confirming-potential-of-deucrictibant-for-on-demand-treatment-of-hae-attacks
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of...
https://www.theafricagazette.com/article/820740021-pharvaris-announces-annual-meeting-of-shareholders
Pharvaris Announces Annual Meeting of Shareholders | The Africa Gazette
The Africa Gazette is an online news publication focusing on the Africa: The latest news from Africa
annual meetingpharvarisannouncesshareholdersafrica